Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

- PMLiVE

First Merck/Samsung biosimilar cleared in South Korea

Approval of Brenzys further opens up competition in biosimilar market

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

Sanofi and Google partner on digital health in diabetes

Aimto develop new patient tools by harnessing data and miniaturised tech

- PMLiVE

Novo Nordisk acquires two US biopharma companies

Strikes deals with Calibrium LLC and MB2

- PMLiVE

FDA clears Jardiance combo for type 2 diabetes

Combination treatment Synjardy is fifth drug to come from Boehringer/Lilly diabetes alliance

- PMLiVE

Novo Nordisk plans $2bn expansion of its diabetes facilities

Comes as the Danish firm prepares to move oral semaglutideinto phase III trials

Eli Lilly HQ

Lilly and Boehringer launch Lantus biosimilar in UK

Competition in the insulin drug market begins to heat up

Could ‘around the pill’ solutions be the key to effective diabetes management?

Published in pharmaphorum July 2015 by Julie Denny

Research Partnership

- PMLiVE

Novo Nordisk’s Victoza fails type 1 diabetes trial

Danish firm’s hopes dashed by latest data

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

- PMLiVE

Intarcia’s diabetes implant beats Merck’s Januvia in trial

New injection-less therapy could revolutionise diabetes treatment

- PMLiVE

Diabetes rates jump by 60% in UK

Comes as new analysis also reveals that 10% of the NHS GP drugs budget spent on the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links